Tirzepatide had an incremental cost-effectiveness ratio of $57,400 per lifetime quality-adjusted life-year (QALY), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback